← Back to Clinical Trials
Recruiting NCT03455478

NCT03455478 Shanghai Eye Study for Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03455478
Status Recruiting
Phase
Sponsor Shanghai Eye Disease Prevention and Treatment Center
Condition Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging
Study Type INTERVENTIONAL
Enrollment 1,000,000 participants
Start Date 2016-01-01
Primary Completion 2019-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type INTERVENTIONAL
Interventions
spectacles

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,000,000 participants in total. It began in 2016-01-01 with a primary completion date of 2019-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in Shanghai. The main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. For this reason, the uncorrected refractive errors of 154,000 senior citizens in Shanghai can be taken as a priority among the public health issues to prevent blindness. Now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on Shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.

Eligibility Criteria

Inclusion Criteria: * shanghai residents aged ≥18 years old Exclusion Criteria: * cognitive and/or mobility disorders; non-shanghai residents; younger than 18 years old.

Contact & Investigator

Central Contact

Xun Xu, MD

✉ drxuxun@tom.com

📞 8613386259538

Frequently Asked Questions

Who can join the NCT03455478 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03455478 currently recruiting?

Yes, NCT03455478 is actively recruiting participants. Contact the research team at drxuxun@tom.com for enrollment information.

Where is the NCT03455478 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT03455478 clinical trial?

NCT03455478 is sponsored by Shanghai Eye Disease Prevention and Treatment Center. The trial plans to enroll 1,000,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology